{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-100156","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2025-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.334816+00:00","generated_at":"2026-05-17T03:12:01.949200+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CorMedix Q3 prelim rev >$100M, raises FY25 pro forma guidance to at least $375M","bullets":["Q3 2025 preliminary net revenue >$100M; DefenCath revenue >$85M; pro forma net revenue >$125M.","FY25 pro forma net revenue guidance raised from $325-350M to at least $375M.","Q3 adjusted EBITDA expected at least $70M; ~$30M cost synergies on run-rate basis by year-end.","Phase III ReSPECT study of Rezzayo fully enrolled; data expected 2Q 2026.","Cash and equivalents ~$56M at Sep 30; projected year-end cash ~$100M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-100156","json":"https://secwatch.observer/filing/0001213900-25-100156.json","markdown":"https://secwatch.observer/filing/0001213900-25-100156.md","text":"https://secwatch.observer/filing/0001213900-25-100156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390025100156/0001213900-25-100156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390025100156/ea0261760-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:12:01.949200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}